CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hepatobiliary and pancreatic cancers.
  
  LEARNING OBJECTIVES

  • Evaluate Phase III data leading to the recent FDA approval of atezolizumab in combination with bevacizumab as first-line therapy for patients with newly diagnosed unresectable or metastatic hepatocellular carcinoma (HCC), and consider the current role of this novel regimen.
  • Recall available clinical trial data with approved and investigational systemic interventions, and where appropriate, apply this information to the current clinical care of patients with locally advanced or metastatic HCC.
  • Maintain an understanding of the side effects and toxicities associated with targeted agents and immunotherapeutic approaches used in the management of advanced HCC, in order to facilitate early and effective responses to various adverse events.
  • Consider age, performance status, prior therapeutic exposure and other clinical and logistical factors in the selection and sequencing of systemic therapy for patients with unresectable or metastatic HCC or locally advanced or metastatic pancreatic adenocarcinoma (PAD).
  • Appreciate the efficacy and tolerability profile of nanoliposomal irinotecan for treatment-refractory metastatic PAD, and optimally incorporate this agent into patient-care algorithms.
  • Appraise available Phase III data leading to the FDA approval of maintenance olaparib after first-line platinum-based chemotherapy for patients with newly diagnosed PAD and a germline BRCA mutation, and consider the diagnostic and therapeutic implications of these findings for clinical practice.
  • Recognize the molecular heterogeneity of cholangiocarcinomas, and apply available clinical research findings in the formation of evidence-based therapeutic approaches for patients with unresectable and metastatic disease.
  • Review the recent FDA approval of pemigatinib for patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 (fibroblast growth factor receptor 2) fusion or other rearrangement, and consider how this agent can be appropriately and safely integrated into clinical management algorithms.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Tanios Bekaii-Saab, MD
  Professor, Mayo Clinic College of Medicine and Science
  Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center
  Consultant, Mayo Clinic in Arizona
  Phoenix, Arizona
  
  Advisory Committee: Immuneering Corporation, Imugene, Sun BioPharma Inc; Consulting Agreements: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celularity, Daiichi Sankyo Inc, Eisai Inc, Exact Sciences, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Natera Inc, Seagen Inc, Sobi, Treos Bio; Contracted Research: AbGenomics, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clovis Oncology, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merus BV, Mirati Therapeutics, Novartis, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc; Data and Safety Monitoring Board/Committee: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Lilly, Merck, Pancreatic Cancer Action Network.
  
  Lipika Goyal, MD, MPhil
  Lead of the Liver Cancer Research Program
  Massachusetts General Hospital Cancer Center
  Assistant Professor
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: Agios Pharmaceuticals Inc, Alentis Therapeutics AG, Debiopharm Group, H3 Biomedicine, Incyte Corporation, QED Therapeutics, Sirtex Medical Ltd, Taiho Oncology Inc; Consulting Agreements: Agios Pharmaceuticals Inc, Alentis Therapeutics AG, Incyte Corporation, QED Therapeutics, Sirtex Medical Ltd, Taiho Oncology Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck and Taiho Oncology Inc.
  
  Release date: January 2021
  Expiration date: January 2022